IBRX Q2 2020 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$436,000+2464.7% YoY

Gross Profit

$436,000100.0% margin

Operating Income

-$51M-11678.0% margin

Net Income

-$51M-11797.9% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+164.2%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$322,000

Balance Sheet

Total Assets

$196M

Total Liabilities

$27M

Stockholders' Equity

$170M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$436,000	$17,000	+2464.7%
Gross Profit	$436,000	$17,000	+2464.7%
Operating Income	-$51M	-$17M	-205.3%
Net Income	-$51M	-$17M	-208.4%